Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Pelthos Therapeutics Inc.AMEX: PTHS
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $0, compared with $621 a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 613 | +56.8% |
| FY2023 | 2023-12-31 | 391 | +252.3% |
| FY2022 | 2022-12-31 | 111 | — |
Common Stock vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 common stock of $0 is the lowest of the 4 companies compared; the peer median is $1.19K.
- Its year-over-year change of -100.0% is the lowest of 4, against a peer median of +333.6%.
- Common stock amounts to 0.0% of total assets for PTHS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $28.73M | +970.0% | +138.5% | 1.2% | |
| Mar 2026 | $1.19K | +211.5% | +128.2% | 0.0% | |
| Mar 2026 | $1.16K | +333.6% | +74.3% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding PTHS) | $1.19K | +333.6% | +128.2% | 0.0% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.